AOU Bologna Policlinico di Sant’Orsola

The research team at AOU Bologna Policlinico di Sant’Orsola is investigating innovative approaches to lower the burden of atherosclerotic cardiovascular disease and related complications. A key study examines whether a novel oral agent can reduce the incidence of major cardiovascular events in patients with established disease and co‑existing chronic kidney disease.

• Atherosclerotic cardiovascular disease
• Chronic kidney disease
• Risk reduction for major cardiovascular events
• Novel oral glucose‑lowering agents

Findings from this work aim to improve long‑term outcomes for individuals at high cardiovascular risk and may expand therapeutic options beyond traditional treatments.

In the digestive disease program, investigators are evaluating a combined regimen of mirikizumab and tirzepatide for patients with active ulcerative colitis who also struggle with obesity or overweight. The goal is to achieve simultaneous clinical remission of intestinal inflammation while promoting meaningful weight loss.

• Ulcerative colitis
• Obesity and overweight
• Combination biologic and metabolic therapy
• Clinical remission and weight reduction

This research reflects the site’s commitment to integrating anti‑inflammatory and metabolic strategies to enhance patient quality of life.